Key points are not available for this paper at this time.
Design
Review
No takes yet. Share an insight, caveat, or question.
Positions selective AT2 agonism as a candidate cardiorenal strategy; leaves open clinical validation in prospective trials.
Helmy M. Siragy (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: